Joseph Douglas Lyon - 01 Dec 2025 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Chief Accounting & Technology Officer
Signature
/s/ Joseph Douglas Lyon
Issuer symbol
CORT
Transactions as of
01 Dec 2025
Net transactions value
-$324,406
Form type
4
Filing time
03 Dec 2025, 20:36:06 UTC
Previous filing
05 Nov 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lyon Joseph Douglas Chief Accounting & Technology Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY /s/ Joseph Douglas Lyon 03 Dec 2025 0001817838

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $67,800 +5,000 +49% $13.56 15,277 01 Dec 2025 Direct F1
transaction CORT Common Stock Sale $397,632 -5,000 -33% $79.53 10,277 01 Dec 2025 Direct F1, F2, F3
transaction CORT Common Stock Award $14,201 +178 +1.7% $79.78 10,455 01 Dec 2025 Direct F1, F4, F5
transaction CORT Common Stock Award $0 +178 +1.7% $0.000000 10,633 01 Dec 2025 Direct F1, F6
transaction CORT Common Stock Tax liability $8,776 -110 -1% $79.78 10,523 02 Dec 2025 Direct F1, F7, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -5,000 -30% $0.000000 11,571 01 Dec 2025 Common Stock 5,000 $13.56 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2 The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
F3 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $79.73 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
F5 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F6 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F7 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F8 The closing price on December 1, 2025 was used to calculate the withholding obligation.
F9 Fully exercisable.

Remarks:

Chief Accounting & Technology Officer